摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,7-二氢-4H-吡喃并[4,3-D]噻唑-2-胺盐酸盐 | 623931-31-7

中文名称
6,7-二氢-4H-吡喃并[4,3-D]噻唑-2-胺盐酸盐
中文别名
6,7-二氢-4H-吡喃o[4,3-d]噻唑-2-胺盐酸盐
英文名称
6,7-dihydro-4H-pyrano[4,3-d][1,3]thiazol-2-amine hydrochloride
英文别名
6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-amine hydrochloride;6,7-dihydro-4H-pyrano[4,3-d][1,3]thiazol-2-amine;hydrochloride
6,7-二氢-4H-吡喃并[4,3-D]噻唑-2-胺盐酸盐化学式
CAS
623931-31-7
化学式
C6H8N2OS*ClH
mdl
——
分子量
192.669
InChiKey
QEKDSMUYYQIGCO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.22
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    76.4
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335

SDS

SDS:3f4e95a87acaba21633061377fd32657
查看

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 6,7-Dihydro-4H-Pyrano[4,3-D]Thiazol-2-Amine
Hydrochloride
: SYX00036
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.


SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 192,67 g/mol
No components need to be disclosed according to the applicable regulations.

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Avoid
breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

SECTION 7: Handling and storage
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    6,7-二氢-4H-吡喃并[4,3-D]噻唑-2-胺盐酸盐3-溴丙酮酸乙酯sodium methylate 作用下, 以 乙醇 为溶剂, 反应 50.5h, 以59%的产率得到ethyl 5,8-dihydro-6H-imidazo[2.1-b]pyrano[4,3-d][1,3]thiazole-2-carboxylate
    参考文献:
    名称:
    Tricyclic 6-alkylidene-penem beta-lactamase inhibitors and beta-lactam antibiotic combination: a broad spectrum antibiotic
    摘要:
    本发明提供了β-内酰胺类抗生素,如头孢吡肟以及化合物I的药物组合物,以及其用于治疗患有细菌感染或疾病的患者的用途。
    公开号:
    US20070027130A1
  • 作为产物:
    描述:
    四氢吡喃酮硫脲磺酰氯 作用下, 以 四氯化碳四氢呋喃乙醇 为溶剂, 反应 12.0h, 以47%的产率得到6,7-二氢-4H-吡喃并[4,3-D]噻唑-2-胺盐酸盐
    参考文献:
    名称:
    Tricyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors
    摘要:
    这项发明涉及某些三环6-烷基亚胺基青霉素,其作为类D酶的抑制剂。β-内酰胺酶水解β-内酰胺类抗生素,因此是细菌抗药性的主要原因。本发明的化合物与β-内酰胺类抗生素结合时,将提供一种有效治疗危及生命的细菌感染的方法。根据本发明,提供了以下公式I的化合物,其用于治疗与类D酶相关的细菌感染:其中:A和B中的一个表示氢,另一个表示可选择取代的融合三环杂芳基团;X为S或O。
    公开号:
    US20060276446A1
点击查看最新优质反应信息

文献信息

  • [EN] HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS BetaEpsilonTauAlpha-LACTAMASE INHIBITORS<br/>[FR] DERIVES D'HETEROTRICYCLYL 6-ALKYLIDENE-PENEMES EN TANT QU'INHIBITEURS DE BETA-LACTAMASE
    申请人:WYETH CORP
    公开号:WO2003093280A1
    公开(公告)日:2003-11-13
    The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.
    本发明提供了一种I式化合物,药物组合物以及其用于治疗患有细菌感染或疾病的患者的用途。
  • Tricyclic 6-alkylidene-penem beta-lactamase inhibitors and beta-lactam antibiotic combination: a broad spectrum antibiotic
    申请人:Mansour S. Tarek
    公开号:US20070027130A1
    公开(公告)日:2007-02-01
    The present invention provides a β-lactam antibiotic such as cefepime and a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.
    本发明提供了β-内酰胺类抗生素,如头孢吡肟以及化合物I的药物组合物,以及其用于治疗患有细菌感染或疾病的患者的用途。
  • Process for preparing 6-alkylidene penem derivatives
    申请人:Wyeth
    公开号:US20040132708A1
    公开(公告)日:2004-07-08
    The present invention provides a process of making compounds of formula I, which are useful for the treatment of bacterial infection or disease. 1
    本发明提供了一种制备式I化合物的方法,该化合物对治疗细菌感染或疾病有用。
  • Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors
    申请人:Wyeth
    公开号:US20040043978A1
    公开(公告)日:2004-03-04
    The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof. 1
    本发明提供了一种化合物I,药物组合物及其用于治疗需要治疗细菌感染或疾病的患者的用途。
  • Tricyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors
    申请人:Venkatesan Aranapakam Mudumbai
    公开号:US20080318921A1
    公开(公告)日:2008-12-25
    The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.
    本发明提供了一种I式化合物、药物组合物及其在治疗需要治疗细菌感染或疾病的患者中的用途。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺